How I Treat AML in 2023 Incorporating the Updated Classifications and Guidelines
Blood · 09.02.2023
DOI: 10.1182/blood.2022017808 ↗Kurz gefasst
Leitlinie in der Zeitschrift Blood, online erschienen am 09.02.2023. Verfasst von Firas El Chaer und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Medicine, University of Virginia, Charlottesville, VA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Hematologic Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.
Abstract (Originalsprache)
The European LeukemiaNet (ELN) recently revised both the clinical (2022) and measurable residual disease (MRD) testing (2021) guidelines for acute myeloid leukemia (AML). Updated World Health Organization (WHO) and an International Consensus Classification (ICC) for myeloid neoplasms were also published in 2022. Together, these documents update the classification, risk stratification, prognostication, monitoring recommendations, and response assessment for patients with AML. Increased appreciation of the genetic drivers of AML over the past decade and our increasingly sophisticated understanding of AML biology have been translated into novel therapies and more complex clinical treatment guidelines. Somatic genetic abnormalities and germline predispositions now define and guide treatment and counseling for subtypes of this hematologic malignancy. In this paper, we discuss how we approach AML in daily clinical practice taking into consideration these recent updates in the context of new treatments and discoveries over the past decade.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Hematology and Oncology, Department of Medicine, University of Virginia, Charlottesville, VA.
- Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
- Myeloid Malignancies Program, National Institutes of Health, Bethesda, MD.
- Section of Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Comprehensive Cancer Center, Yale University, New Haven, CT.
ORCID-Profile: Firas El Chaer, Christopher S Hourigan, Amer M Zeidan
Förderung
- NCATS NIH HHS
Zitieren
APA
El Chaer, F., Hourigan, C. S., & Zeidan, A. M. (2023). How I Treat AML in 2023 Incorporating the Updated Classifications and Guidelines. Blood. https://doi.org/10.1182/blood.2022017808
Vancouver
El Chaer F, Hourigan CS, Zeidan AM. How I Treat AML in 2023 Incorporating the Updated Classifications and Guidelines. Blood. 2023. doi:10.1182/blood.2022017808
BibTeX
@article{ElChaer2023,
author = {El Chaer, Firas and Hourigan, Christopher S and Zeidan, Amer M},
title = {How I Treat AML in 2023 Incorporating the Updated Classifications and Guidelines},
journal = {Blood},
year = {2023},
doi = {10.1182/blood.2022017808}
}
EUVIMED